---
figid: PMC5499780__tcrm-13-799Fig1
figtitle: 'Action of lenvatinib and everolimus.Notes: Lenvatinib inhibits RTKs on
  endothelial cell and cancer cell'
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- AKT8 retrovirus
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC5499780
filename: tcrm-13-799Fig1.jpg
figlink: /pmc/articles/PMC5499780/figure/f1-tcrm-13-799/
number: F1
caption: 'Mechanisms of action of lenvatinib and everolimus.Notes: Lenvatinib inhibits
  RTKs on endothelial cell and cancer cell. Activated VEGFR and FGFR on endothelial
  cell trigger the MAPK/ERK pathway that promotes angiogenesis. On cancer cell, activated
  RTKs (ie, VEGFR, PDGFR-β, RET, c-KIT, and FGFR) mediate cell proliferation through
  the MAPK/ERK pathway; the activation of PI3K/AKT/mTOR pathway leads to cell survival,
  growth, and motility. Everolimus inhibits mTOR signaling. HIF is degraded by VHL
  in normoxic condition; in the presence of hypoxia, or when overexpressed, it promotes
  angiogenesis through the synthesis of growth factors. Dashed arrows indicate crosslinks
  between different signaling pathways: RAS activates PI3K, whereas mTOR promotes
  HIF expression.Abbreviations: VEGF, vascular endothelial growth factor; PDGF, platelet-derived
  growth factor; TGF-β, transforming growth factor beta; VEGFR, vascular endothelial
  growth factor receptor; PDGFR, platelet-derived growth factor receptor; FGFR, fibroblast
  growth factor receptor; RTK, receptor tyrosine kinase; MAPK, mitogen-activated protein
  kinase; ERK, extracellular signal regulated kinase; PI3K, phosphoinositide 3-kinase;
  mTOR, mammalian target of rapamycin; HIF, hypoxia-inducible factor; VHL, von Hippel–Lindau;
  PDK, pyruvate dehydrogenase kinase; RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma;
  MEK, mitogen-activated protein extracellular signal-regulated kinase kinase; ERK,
  extracellular signal-regulated kinase; PIP, phosphatidylinositol phosphate; AKT,
  protein kinase B kinase (AKT8 virus oncogene cellular homolog).'
papertitle: Clinical use of lenvatinib in combination with everolimus for the treatment
  of advanced renal cell carcinoma.
reftext: Alessandro Leonetti, et al. Ther Clin Risk Manag. 2017;13:799-806.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9777896
figid_alias: PMC5499780__F1
figtype: Figure
redirect_from: /figures/PMC5499780__F1
ndex: ecdd3486-deb8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5499780__tcrm-13-799Fig1.html
  '@type': Dataset
  description: 'Mechanisms of action of lenvatinib and everolimus.Notes: Lenvatinib
    inhibits RTKs on endothelial cell and cancer cell. Activated VEGFR and FGFR on
    endothelial cell trigger the MAPK/ERK pathway that promotes angiogenesis. On cancer
    cell, activated RTKs (ie, VEGFR, PDGFR-β, RET, c-KIT, and FGFR) mediate cell proliferation
    through the MAPK/ERK pathway; the activation of PI3K/AKT/mTOR pathway leads to
    cell survival, growth, and motility. Everolimus inhibits mTOR signaling. HIF is
    degraded by VHL in normoxic condition; in the presence of hypoxia, or when overexpressed,
    it promotes angiogenesis through the synthesis of growth factors. Dashed arrows
    indicate crosslinks between different signaling pathways: RAS activates PI3K,
    whereas mTOR promotes HIF expression.Abbreviations: VEGF, vascular endothelial
    growth factor; PDGF, platelet-derived growth factor; TGF-β, transforming growth
    factor beta; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived
    growth factor receptor; FGFR, fibroblast growth factor receptor; RTK, receptor
    tyrosine kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular signal
    regulated kinase; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin;
    HIF, hypoxia-inducible factor; VHL, von Hippel–Lindau; PDK, pyruvate dehydrogenase
    kinase; RAS, rat sarcoma; RAF, rapidly accelerated fibrosarcoma; MEK, mitogen-activated
    protein extracellular signal-regulated kinase kinase; ERK, extracellular signal-regulated
    kinase; PIP, phosphatidylinositol phosphate; AKT, protein kinase B kinase (AKT8
    virus oncogene cellular homolog).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pdk1
  - Pdpk1
  - Vegfa
  - Tgfb1
  - Ltbp1
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Akt1
  - Mdk
  - Mtor
  - Ephb2
  - Mapk1
  - Vhl
  - KDR
  - FLT1
  - FLT4
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - PDK1
  - PDPK1
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - TGFB1
  - TGFB2
  - TGFB3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - EPHB2
  - MAPK1
  - MAPK3
  - VHL
  - Pik3cg
  - Ephb1
  - Pvr
  - btl
  - htl
  - Pvf1
  - Pvf2
  - Pvf3
  - dpp
  - gbb
  - put
  - mav
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Ras64B
  - Ras85D
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Tor
  - Erk7
  - rl
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Lenvatinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
